Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 16,138 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Breast Cancer, Cancer of the Breast
Interventions: Physical Activity Intervention; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Joint Loosening Yoga; Behavioral
Lead sponsor: AshtaYoga, LLC; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Interventions: ADX-097; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina

Conditions: Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions: Not listed
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Depression, Fatigue, Sleep Disorders
Interventions: Yoga, Education; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions: Total Hip Replacement; Device
Lead sponsor: Anderson Orthopaedic Research Institute; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more

Conditions: Breast Cancer, Risk Reduction
Interventions: Breast Cancer Risk Assessment; Diagnostic Test
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Melanoma
Interventions: LL37, Photographs; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Carcinoma of the Breast
Interventions: Paclitaxel, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 20
States / cities: San Francisco, California • Maywood, Illinois • Indianapolis, Indiana + 13 more

Conditions: Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions: alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neoplasms
Interventions: BAY 1238097; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne
Interventions: Geologie Acne Regimen - one side of face, Proactive Acne Regimen - other side of face; Combination Product
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Breast Cancer
Interventions: questionnaires, audio recordings , questionnaires, audio recorded questionnaires; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Commack, New York • New York, New York • Sleepy Hollow, New York

Conditions: Atopic Dermatitis, Eczema
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more

Conditions: Contact Allergic Dermatitis, Adverse Skin Reaction
Interventions: Aquacel dressing; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma
Interventions: Relatlimab, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • San Luis Obispo, California + 17 more

Conditions: Scleroderma, Systemic
Interventions: Making it Work Systemic Sclerosis; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 67 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Diabetic Foot Ulcer
Interventions: Corlicyte; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
Interventions: Bacitracin, AmeriGel®, Vitamin C; Drug · Dietary Supplement
Lead sponsor: Susan Hassenbein; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Abnormal Elastogenesis, Vascular Diseases, Connective Tissue Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Erythropoietic Protoporphyria
Interventions: DISC-1459; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more

Conditions: Breast Cancer, Breast Neoplasm Female
Interventions: Walking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)

Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy

Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

BC Risk Assessment Before Top Surgery

Intratumoral Injections of LL37 for Melanoma

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

BAY1238097, First in Man

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Aquacel Hypersensitivity Dressing in TJAs

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Making it Work Program for Systemic Sclerosis

PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS

The Relationship of Hemoglobin A1c and Diabetic Wound Healing

Gene First Approach to Connective Tissue Disease

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Study on Physical Activity's Relationship With Cancer and Cognition